Sulopenem was superior to amoxicillin/clavulanate and ciprofloxacin in treating antimicrobial resistant uncomplicated urinary tract infections. The antibiotic was safe and...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible...

A phase 3 trial showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo. Hyperkalemia was greater...

Xdemvy is the first and only approved FDA treatment for Demodex blepharitis Xdemvy can achieve collarette reduction of no more...

Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...

Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution...

As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59%...

Capvaxive covers roughly 84% of serotypes responsible for pneumococcal disease in adults 50 years and older. Capvaxive is non-inferior to...

1. Onyda XR is the only non-stimulant medication with nighttime dosing indications. 2. Onyda XR can be added as an...

Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function...